» Articles » PMID: 36228112

Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Abstract

Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.

Citing Articles

Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy.

Shahab M, Al-Madhagi H, Zheng G, Zeb A, Alasmari A, Alharbi M Sci Rep. 2023; 13(1):14466.

PMID: 37660065 PMC: 10475047. DOI: 10.1038/s41598-023-41325-9.


Integrating Bioinformatics and Drug Sensitivity Analyses to Identify Molecular Characteristics Associated with Targeting Necroptosis in Breast Cancer and their Clinical Prognostic Significance.

Zheng C, Guo H, Mo Y, Liu G Recent Pat Anticancer Drug Discov. 2023; 19(5):681-694.

PMID: 37653627 DOI: 10.2174/1574892819666230831112815.


Targeting nuclear hormone receptors for the prevention of breast cancer.

Moyer C, Brown P Front Med (Lausanne). 2023; 10:1200947.

PMID: 37583424 PMC: 10424511. DOI: 10.3389/fmed.2023.1200947.

References
1.
Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V . Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002; 138(3):325-32. DOI: 10.1001/archderm.138.3.325. View

2.
Li Y, Zhang Y, Hill J, Kim H, Shen Q, Bissonnette R . The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer. 2008; 98(8):1380-8. PMC: 2361704. DOI: 10.1038/sj.bjc.6604320. View

3.
Grubbs C, Lubet R, Atigadda V, Christov K, Deshpande A, Tirmal V . Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis. 2005; 27(6):1232-9. DOI: 10.1093/carcin/bgi308. View

4.
Theodosiou M, Laudet V, Schubert M . From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci. 2010; 67(9):1423-45. PMC: 11115864. DOI: 10.1007/s00018-010-0268-z. View

5.
Grubbs C, Hill D, Bland K, Beenken S, Lin T, Eto I . 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett. 2003; 201(1):17-24. DOI: 10.1016/s0304-3835(03)00461-0. View